CDMO Irvine Pharmaceutical Services has announced that it will open a new 115,000 sq ft analytical facility in Hangzhou, China, the company said. The Hangzhou location should be fully operational in early 2015.
While Irvine’s California facilities offer a number of inhalation and intranasal product analytical testing services, the only OINDP-related service the Chinese location will offer for the tie being is extractables/leachables testing.
Irvine CEO and Founder Assad J. Kazeminy commented, “Irvine is responding to the rising needs of large multi-national pharmaceutical companies that are looking for contract organizations overseas that include robust cGMP quality infrastructure and technical expertise. Irvine will now have a local presence and a strong understanding of the local market to offer the region high quality analytical support.”
Read the Irvine Pharma press release.
